Davita Inc (NYSE:DVA) insider James K. Hilger sold 3,572 shares of the business’s stock in a transaction that occurred on Tuesday, January 16th. The stock was sold at an average price of $78.95, for a total transaction of $282,009.40. Following the transaction, the insider now owns 33,649 shares of the company’s stock, valued at approximately $2,656,588.55. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.
Shares of Davita Inc (NYSE DVA) traded down $0.87 during trading on Thursday, reaching $78.19. 1,082,874 shares of the company’s stock were exchanged, compared to its average volume of 1,595,100. The company has a debt-to-equity ratio of 1.79, a current ratio of 1.40 and a quick ratio of 1.35. Davita Inc has a twelve month low of $52.51 and a twelve month high of $80.71. The firm has a market cap of $14,400.00, a price-to-earnings ratio of 29.96 and a beta of 0.96.
Davita (NYSE:DVA) last issued its quarterly earnings results on Tuesday, November 7th. The company reported $0.81 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.94 by ($0.13). The company had revenue of $3.92 billion for the quarter, compared to analyst estimates of $3.91 billion. Davita had a net margin of 3.40% and a return on equity of 13.31%. The company’s revenue for the quarter was up 5.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.95 EPS. equities research analysts anticipate that Davita Inc will post 3.42 EPS for the current fiscal year.
DVA has been the topic of a number of recent analyst reports. TheStreet upgraded shares of Davita from a “c” rating to a “b-” rating in a research note on Thursday, January 4th. Citigroup upgraded shares of Davita from a “neutral” rating to a “buy” rating and upped their price target for the company from $67.71 to $82.00 in a research note on Monday, December 11th. Bank of America upgraded shares of Davita from a “neutral” rating to a “buy” rating and upped their price target for the company from $75.00 to $85.00 in a research note on Thursday, January 4th. Robert W. Baird restated a “buy” rating and set a $95.00 price target (up previously from $82.00) on shares of Davita in a research note on Friday, January 12th. Finally, SunTrust Banks set a $70.00 price target on shares of Davita and gave the company a “hold” rating in a research note on Thursday, December 7th. Two investment analysts have rated the stock with a sell rating, five have issued a hold rating, four have assigned a buy rating and two have issued a strong buy rating to the stock. The stock currently has a consensus rating of “Hold” and an average price target of $78.22.
Hedge funds have recently added to or reduced their stakes in the company. Migdal Insurance & Financial Holdings Ltd. purchased a new stake in shares of Davita in the 3rd quarter valued at $154,000. Country Club Trust Company n.a. purchased a new stake in shares of Davita in the 4th quarter valued at $207,000. Berkshire Asset Management LLC PA purchased a new stake in shares of Davita in the 4th quarter valued at $234,000. Oakbrook Investments LLC purchased a new stake in shares of Davita in the 4th quarter valued at $415,000. Finally, CAPROCK Group Inc. boosted its holdings in shares of Davita by 53.2% in the 4th quarter. CAPROCK Group Inc. now owns 6,290 shares of the company’s stock valued at $498,000 after acquiring an additional 2,183 shares during the last quarter. 87.97% of the stock is currently owned by institutional investors and hedge funds.
COPYRIGHT VIOLATION WARNING: This story was originally reported by American Banking News and is owned by of American Banking News. If you are viewing this story on another site, it was illegally copied and republished in violation of U.S. and international copyright & trademark legislation. The correct version of this story can be viewed at https://www.americanbankingnews.com/2018/01/18/insider-selling-davita-inc-dva-insider-sells-3572-shares-of-stock.html.
Davita Company Profile
DaVita Inc, formerly DaVita HealthCare Partners Inc, operates two divisions: DaVita Kidney Care (Kidney Care) and DaVita Medical Group (DMG). The Kidney Care division consists of its the United States dialysis and related lab services, its ancillary services and strategic initiatives, including its international operations, and its corporate administrative support.
Receive News & Ratings for Davita Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Davita and related companies with MarketBeat.com's FREE daily email newsletter.